194 related articles for article (PubMed ID: 1373381)
1. Intramolecular relationships in cholinesterases revealed by oocyte expression of site-directed and natural variants of human BCHE.
Neville LF; Gnatt A; Loewenstein Y; Seidman S; Ehrlich G; Soreq H
EMBO J; 1992 Apr; 11(4):1641-9. PubMed ID: 1373381
[TBL] [Abstract][Full Text] [Related]
2. Anionic site interactions in human butyrylcholinesterase disrupted by two single point mutations.
Neville LF; Gnatt A; Padan R; Seidman S; Soreq H
J Biol Chem; 1990 Dec; 265(34):20735-8. PubMed ID: 2249982
[TBL] [Abstract][Full Text] [Related]
3. Molecular dissection of cholinesterase domains responsible for carbamate toxicity.
Loewenstein Y; Denarie M; Zakut H; Soreq H
Chem Biol Interact; 1993 Jun; 87(1-3):209-16. PubMed ID: 8343977
[TBL] [Abstract][Full Text] [Related]
4. Chimeric human cholinesterase. Identification of interaction sites responsible for recognition of acetyl- or butyrylcholinesterase-specific ligands.
Loewenstein Y; Gnatt A; Neville LF; Soreq H
J Mol Biol; 1993 Nov; 234(2):289-96. PubMed ID: 8230213
[TBL] [Abstract][Full Text] [Related]
5. Evolution of acetylcholinesterase and butyrylcholinesterase in the vertebrates: an atypical butyrylcholinesterase from the Medaka Oryzias latipes.
Pezzementi L; Nachon F; Chatonnet A
PLoS One; 2011 Feb; 6(2):e17396. PubMed ID: 21364766
[TBL] [Abstract][Full Text] [Related]
6. Site-directed mutagenesis of active site residues reveals plasticity of human butyrylcholinesterase in substrate and inhibitor interactions.
Gnatt A; Loewenstein Y; Yaron A; Schwarz M; Soreq H
J Neurochem; 1994 Feb; 62(2):749-55. PubMed ID: 8294937
[TBL] [Abstract][Full Text] [Related]
7. Aromatic amino-acid residues at the active and peripheral anionic sites control the binding of E2020 (Aricept) to cholinesterases.
Saxena A; Fedorko JM; Vinayaka CR; Medhekar R; Radić Z; Taylor P; Lockridge O; Doctor BP
Eur J Biochem; 2003 Nov; 270(22):4447-58. PubMed ID: 14622273
[TBL] [Abstract][Full Text] [Related]
8. Overlapping drug interaction sites of human butyrylcholinesterase dissected by site-directed mutagenesis.
Loewenstein-Lichtenstein Y; Glick D; Gluzman N; Sternfeld M; Zakut H; Soreq H
Mol Pharmacol; 1996 Dec; 50(6):1423-31. PubMed ID: 8967962
[TBL] [Abstract][Full Text] [Related]
9. Specificity of ethephon as a butyrylcholinesterase inhibitor and phosphorylating agent.
Haux JE; Lockridge O; Casida JE
Chem Res Toxicol; 2002 Dec; 15(12):1527-33. PubMed ID: 12482234
[TBL] [Abstract][Full Text] [Related]
10. Amino acid residues involved in stereoselective inhibition of cholinesterases with bambuterol.
Bosak A; Gazić I; Vinković V; Kovarik Z
Arch Biochem Biophys; 2008 Mar; 471(1):72-6. PubMed ID: 18167304
[TBL] [Abstract][Full Text] [Related]
11. Aspartate-70 to glycine substitution confers resistance to naturally occurring and synthetic anionic-site ligands on in-ovo produced human butyrylcholinesterase.
Neville LF; Gnatt A; Loewenstein Y; Soreq H
J Neurosci Res; 1990 Dec; 27(4):452-60. PubMed ID: 2079709
[TBL] [Abstract][Full Text] [Related]
12. Structure-function relationship studies in human cholinesterases reveal genomic origins for individual variations in cholinergic drug responses.
Loewenstein Y; Gnatt A; Neville LF; Zakut H; Soreq H
Prog Neuropsychopharmacol Biol Psychiatry; 1993 Nov; 17(6):905-26. PubMed ID: 8278601
[TBL] [Abstract][Full Text] [Related]
13. Differences in active-site gorge dimensions of cholinesterases revealed by binding of inhibitors to human butyrylcholinesterase.
Saxena A; Redman AM; Jiang X; Lockridge O; Doctor BP
Chem Biol Interact; 1999 May; 119-120():61-9. PubMed ID: 10421439
[TBL] [Abstract][Full Text] [Related]
14. Amino acid residues involved in the interaction of acetylcholinesterase and butyrylcholinesterase with the carbamates Ro 02-0683 and bambuterol, and with terbutaline.
Kovarik Z; Radić Z; Grgas B; Skrinjarić-Spoljar M; Reiner E; Simeon-Rudolf V
Biochim Biophys Acta; 1999 Aug; 1433(1-2):261-71. PubMed ID: 10446376
[TBL] [Abstract][Full Text] [Related]
15. Acetylcholinesterase active centre and gorge conformations analysed by combinatorial mutations and enantiomeric phosphonates.
Kovarik Z; Radić Z; Berman HA; Simeon-Rudolf V; Reiner E; Taylor P
Biochem J; 2003 Jul; 373(Pt 1):33-40. PubMed ID: 12665427
[TBL] [Abstract][Full Text] [Related]
16. Differences in active site gorge dimensions of cholinesterases revealed by binding of inhibitors to human butyrylcholinesterase.
Saxena A; Redman AM; Jiang X; Lockridge O; Doctor BP
Biochemistry; 1997 Dec; 36(48):14642-51. PubMed ID: 9398183
[TBL] [Abstract][Full Text] [Related]
17. Genetic predisposition to adverse consequences of anti-cholinesterases in 'atypical' BCHE carriers.
Loewenstein-Lichtenstein Y; Schwarz M; Glick D; Nørgaard-Pedersen B; Zakut H; Soreq H
Nat Med; 1995 Oct; 1(10):1082-5. PubMed ID: 7489367
[TBL] [Abstract][Full Text] [Related]
18. Toluidine blue O is a potent inhibitor of human cholinesterases.
Biberoglu K; Tek MY; Ghasemi ST; Tacal O
Arch Biochem Biophys; 2016 Aug; 604():57-62. PubMed ID: 27296777
[TBL] [Abstract][Full Text] [Related]
19. Tetramerization domain of human butyrylcholinesterase is at the C-terminus.
Blong RM; Bedows E; Lockridge O
Biochem J; 1997 Nov; 327 ( Pt 3)(Pt 3):747-57. PubMed ID: 9581552
[TBL] [Abstract][Full Text] [Related]
20. Wild-type and A328W mutant human butyrylcholinesterase tetramers expressed in Chinese hamster ovary cells have a 16-hour half-life in the circulation and protect mice from cocaine toxicity.
Duysen EG; Bartels CF; Lockridge O
J Pharmacol Exp Ther; 2002 Aug; 302(2):751-8. PubMed ID: 12130740
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
